LAURUSLABS1,942.50

Laurus Labs Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersDIVISLABGLANDMANKINDBIOCONALKEMLUPINFORTISGLENMARKMcap ₹1.05L Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,224.51,194.91,439.71,194.91,223.71,415.11,720.31,569.63,223.01,778.31,811.62,026.3
Other Income1.82.418.52.54.69.458.610.437.45.811.89.2
Total Income1,226.21,197.41,458.21,197.41,228.31,424.51,778.91,580.03,260.41,784.11,823.42,035.5
Expenses
+ Cost of Materials Consumed673.4634.1591.4572.1577.2653.0626.3599.41,276.2725.3792.9785.8
+ Purchases of Stock-in-Trade26.317.540.822.725.634.822.338.569.255.148.235.1
+ Changes in Inventories-118.6-106.389.8-57.9-54.5-77.6134.0-0.6-44.6-85.9-141.0-64.9
+ Employee Benefit Expense163.9155.0161.1174.0178.7189.1177.7214.8430.4229.2235.9258.7
+ Finance Costs42.450.850.549.252.657.856.451.591.538.840.442.2
+ Depreciation & Amortisation93.498.4102.3106.1107.5106.1110.4116.8237.3120.6122.1123.9
+ Other Expenses291.6313.1315.1312.9318.4330.6339.3335.3706.5374.3363.5373.3
Total Expenses1,172.31,162.71,350.91,179.01,205.51,293.81,466.51,355.82,766.51,457.51,462.01,554.1
EBITDA187.9181.4241.5171.2178.3285.2420.6382.1785.4480.2512.1638.3
EBIT94.583.0139.265.170.8179.1310.2265.3548.1359.6390.0514.4
Profit
PBT before Exceptional Items53.934.6107.318.522.8130.7312.3224.2494.0326.6361.4481.4
Pretax Income53.934.6107.318.522.8130.7312.3224.2494.0326.6361.4481.4
+ Current Tax15.318.443.418.423.235.080.360.0147.971.578.1134.9
+ Deferred Tax-0.7-9.0-11.4-12.2-18.15.1-1.93.1-8.82.01.3-15.5
Tax Expense14.69.532.06.35.140.178.563.1139.173.579.5119.4
+ Share of Associates & JVs-2.2-1.8-0.30.52.22.3-1.10.61.3-1.20.20.1
Net Income37.123.375.012.720.092.9232.8161.7356.2251.9282.1362.1
+ Net Income — Continuing Ops39.325.275.312.217.790.6233.9161.1354.8253.1281.9362.0
+ Other Comprehensive Income-1.7-1.12.30.3-0.4-1.5-2.1-0.7-6.4-1.62.1-2.2
Total Comprehensive Income35.522.377.313.019.591.5230.7161.0349.8250.3284.2359.9
Net Income to Common37.023.175.612.519.892.3233.7163.0358.0251.7279.1367.6
Minority Interest0.20.2-0.60.20.10.6-0.9-1.3-1.80.23.0-5.5
Per Share
Basic EPS0.690.431.400.230.371.714.343.026.634.675.176.81
Diluted EPS0.680.431.400.230.371.714.333.026.634.655.176.80
Other Comprehensive Income — detail
+ Other Comprehensive Income-2.1-0.7-6.4-1.62.1-2.2
+ Items NOT to be Reclassified to P&L-1.6-1.63.70.40.30.3-2.2-0.3-0.4-1.75.0-2.4
+ Tax on Items NOT to be Reclassified0.0-0.10.00.00.0-0.6
+ Tax on Items NOT to be Reclassified — alt tag-0.4-0.40.90.10.00.0
+ Items to be Reclassified to P&L-0.4-0.50.0-0.7-1.80.2-0.5-6.00.1-2.9-0.4
+ Tax on Items to be Reclassified — alt tag0.0-0.20.00.00.00.0
Comprehensive Income — Owners of Parent35.322.177.912.819.490.8231.6162.3351.6250.1281.2365.4
Comprehensive Income — Non-controlling Interests0.20.2-0.60.20.10.6-0.9-1.3-1.80.22.9-5.5
Per Share — as-filed variants
Basic EPS — Continuing Operations0.690.431.400.230.371.714.343.026.634.675.176.81
Diluted EPS — Continuing Operations0.680.431.400.230.371.714.333.026.634.655.176.80
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit643.4649.5717.7658.1675.4804.9937.6932.21,922.31,083.71,111.51,270.3
Gross Margin %52.5454.3649.8555.0755.1956.8854.5059.3959.6460.9461.3562.69
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)53.934.6107.318.522.8130.7312.3224.2494.0326.6361.4481.4
Net Income Adj (tax-effected)37.123.375.012.720.092.9232.8161.7356.2251.9282.1362.1
EPS Adj0.690.431.400.230.371.714.343.026.634.675.176.81
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital107.7107.8107.8107.8107.8107.9107.9108.0108.0108.0108.0108.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.